GNFT
Price
$3.41
Change
+$0.01 (+0.29%)
Updated
Apr 3, 04:56 PM (EDT)
Capitalization
176.43M
20 days until earnings call
LSB
Price
$2.33
Change
+$0.04 (+1.75%)
Updated
Apr 3, 04:21 PM (EDT)
Capitalization
44.48M
Ad is loading...

GNFT vs LSB

Header iconGNFT vs LSB Comparison
Open Charts GNFT vs LSBBanner chart's image
Genfit SA
Price$3.41
Change+$0.01 (+0.29%)
Volume$100
Capitalization176.43M
LakeShore Biopharma
Price$2.33
Change+$0.04 (+1.75%)
Volume$300
Capitalization44.48M
GNFT vs LSB Comparison Chart
Loading...
LSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GNFT vs. LSB commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GNFT is a Buy and LSB is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (GNFT: $3.41 vs. LSB: $2.33)
Brand notoriety: GNFT and LSB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GNFT: 111% vs. LSB: 160%
Market capitalization -- GNFT: $176.43M vs. LSB: $44.48M
GNFT [@Biotechnology] is valued at $176.43M. LSB’s [@Biotechnology] market capitalization is $44.48M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GNFT’s FA Score shows that 0 FA rating(s) are green whileLSB’s FA Score has 1 green FA rating(s).

  • GNFT’s FA Score: 0 green, 5 red.
  • LSB’s FA Score: 1 green, 4 red.
According to our system of comparison, both GNFT and LSB are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LSB’s TA Score shows that 4 TA indicator(s) are bullish.

  • LSB’s TA Score: 4 bullish, 6 bearish.

Price Growth

GNFT (@Biotechnology) experienced а -3.94% price change this week, while LSB (@Biotechnology) price change was -6.80% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.91%. For the same industry, the average monthly price growth was -11.19%, and the average quarterly price growth was -14.86%.

Reported Earning Dates

GNFT is expected to report earnings on May 22, 2025.

Industries' Descriptions

@Biotechnology (-8.91% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GNFT($176M) has a higher market cap than LSB($44.5M). GNFT YTD gains are higher at: -8.479 vs. LSB (-32.633).
GNFTLSBGNFT / LSB
Capitalization176M44.5M396%
EBITDAN/A-220.1M-
Gain YTD-8.479-32.63326%
P/E Ratio8.54N/A-
RevenueN/A672M-
Total CashN/A49.5M-
Total DebtN/A369M-
FUNDAMENTALS RATINGS
GNFT: Fundamental Ratings
GNFT
OUTLOOK RATING
1..100
21
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
60
P/E GROWTH RATING
1..100
83
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
LSB
RSI
ODDS (%)
Bearish Trend 2 days ago
47%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
39%
Momentum
ODDS (%)
Bullish Trend 2 days ago
51%
MACD
ODDS (%)
Bullish Trend 2 days ago
56%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
69%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
46%
Advances
ODDS (%)
Bullish Trend 14 days ago
72%
Declines
ODDS (%)
Bearish Trend 2 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
44%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
LSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AZMIX16.42N/A
N/A
Virtus NFJ Emerging Markets Value Ins
CLSPX25.50N/A
N/A
Columbia Select Mid Cap Gro Fd I
OAKBX36.31N/A
N/A
Oakmark Equity And Income Investor
NWHUX27.60N/A
N/A
Nationwide Bailard Tech & Sci Instl Svc
GLVAX75.79N/A
N/A
Invesco Global Focus A

GNFT and

Correlation & Price change

A.I.dvisor indicates that over the last year, GNFT has been loosely correlated with SPRB. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if GNFT jumps, then SPRB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GNFT
1D Price
Change %
GNFT100%
-3.52%
SPRB - GNFT
39%
Loosely correlated
+9.21%
CVALF - GNFT
25%
Poorly correlated
-3.75%
ORMP - GNFT
25%
Poorly correlated
+3.29%
GLTO - GNFT
25%
Poorly correlated
+14.54%
CAPR - GNFT
24%
Poorly correlated
+2.80%
More

LSB and

Correlation & Price change

A.I.dvisor indicates that over the last year, LSB has been loosely correlated with STTK. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if LSB jumps, then STTK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LSB
1D Price
Change %
LSB100%
+1.79%
STTK - LSB
38%
Loosely correlated
-17.34%
BCTX - LSB
30%
Poorly correlated
-2.08%
GLTO - LSB
29%
Poorly correlated
-11.46%
GNFT - LSB
23%
Poorly correlated
+0.29%
DSGN - LSB
21%
Poorly correlated
-7.12%
More